Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V180 Dengue Vaccine in Healthy Adults Previously Vaccinated With TV003 or TV005
NCT02450838Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2015
- Primary completion
- Oct 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of V180 + ISCOMATRIX in dengue fever (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Virus neutralizing antibody levels at Day 28. Started Apr 2015; status: completed.
02
Drugs
V180 + ISCOMATRIX
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT02450838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02450838.